TUHURA BIOSCIENCES INCHURA
ASignal's systematic analysis rates HURA as Bearish.
Reflects the latest available analysis · analyzed Oct 22, 2026
The case on HURA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Price above 20-day SMA indicating potential short-term uptrend
- RSI near neutral (55.5), not overbought
- MACD histogram improving (positive momentum shift)
- Negative operating and free cash flow
- Negative return on equity (-161.39%) and return on assets (-58.43%)
- Extremely weak liquidity (current ratio 0.18x, quick ratio 0.14x)
- No revenue or earnings growth data available
- High debt-to-equity ratio (0.50x) for a biotech with no profitability
- Negative enterprise value to EBITDA (-4.57x) indicating valuation concerns
See the full verdict on HURA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes HURA
Most investors never get a second opinion, let alone several. ASignal runs HURA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.